Biotechnology company STORM Therapeutics has announced it has secured $56 million in a Series C financing to support its sarcoma treatment. The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. This extends to funding the company’s Phase II monotherapy study in selected sarcoma indications, in which the first patient has now been […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!